New drug shows promise for kids with sudden OCD and tics?
NCT ID NCT04508530
First seen Jan 09, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This study tested a medicine called Panzyga (an immunoglobulin) against a placebo in 71 children aged 6 to 17 with PANS/PANDAS, a condition causing sudden severe OCD and other symptoms. The main goal was to see if Panzyga reduced OCD symptoms more than placebo after 9 weeks. Researchers measured changes using a standard OCD rating scale.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Octapharma Research Site
Tucson, Arizona, 85712, United States
-
Octapharma Research Site
Little Rock, Arkansas, 72202, United States
-
Octapharma Research Site
Los Angeles, California, 90024, United States
-
Octapharma Research Site
Palo Alto, California, 94305, United States
-
Octapharma Research Site
Centennial, Colorado, 80112, United States
-
Octapharma Research Site
Boston, Massachusetts, 02114, United States
-
Octapharma Research Site
Lebanon, New Hampshire, 03756, United States
-
Octapharma Research Site
Genova, 16147, Italy
-
Octapharma Research Site
Roma, 00161, Italy
-
Octapharma Research Site
Roma, 00186, Italy
-
Octapharma Research Site
Gothenburg, 41685, Sweden
-
Octapharma Research Site
Stockholm, 17164, Sweden
Conditions
Explore the condition pages connected to this study.